Literature DB >> 19350245

Major prognostic impact of persistent microvascular obstruction as assessed by contrast-enhanced cardiac magnetic resonance in reperfused acute myocardial infarction.

Alexandre A Cochet1, Luc Lorgis, Alain Lalande, Marianne Zeller, Jean-Claude Beer, Paul M Walker, Claude Touzery, Jean-Eric Wolf, François Brunotte, Yves Cottin.   

Abstract

The aim of this study was to compare the prognostic significance of microvascular obstruction (MO) and persistent microvascular obstruction (PMO) as assessed by cardiac magnetic resonance (CMR) in patients with acute myocardial infarction (AMI). CMR was performed in 184 patients within the week following successfully reperfused first AMI. First-pass images were performed to evaluate extent of MO and late gadolinium-enhanced images to assess PMO and infarct size (IS). Major adverse cardiac events (MACE) were collected at 1-year follow-up. MO and PMO were found in 127 (69%) and 87 (47%) patients, respectively. By using univariate logistic regression analysis, high Global Registry of Acute Coronary Events (GRACE) risk score (odds ratio [OR] 95% confidence interval [CI]: 3.6 [1.8-7.4], p < 0.001), IS greater than 10% (OR [95% CI]: 2.7 [1.1-6.9], p = 0.036), left ventricular ejection fraction less than 40% (OR [95% CI]: 2.4 [1.1-5.2], p = 0.027), presence of MO (OR [95% CI]: 3.1 [1.3-7.3], p = 0.004) and presence of PMO (OR [95% CI]:10 [4.1-23.9], p < 0.001) were shown to be significantly associated with the outcome. By using multivariate analysis, presence of MO (OR [95% CI]: 2.5 [1.0-6.2], p = 0.045) or of PMO (OR [95% CI]: 8.7 [3.6-21.1], p < 0.001), associated with GRACE score, were predictors of MACE. Presence of microvascular obstruction and persistent microvascular obstruction is very common in AMI patients even after successful reperfusion and is associated with a dramatically higher risk of subsequent cardiovascular events, beyond established prognostic markers. Moreover, our data suggest that the prognostic impact of PMO might be superior to MO.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19350245     DOI: 10.1007/s00330-009-1395-5

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  32 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  Using a contrast-enhanced imaging sequence at 3-minute delay in 3-T magnetic resonance imaging for acute infarct evaluation.

Authors:  Alexandre Comte; Bruno Kastler; Laurent Laborie; Georges Hadjidekov; Nicolas Meneveau; Hatem Boulahdour
Journal:  Invest Radiol       Date:  2008-09       Impact factor: 6.016

3.  An improved MR imaging technique for the visualization of myocardial infarction.

Authors:  O P Simonetti; R J Kim; D S Fieno; H B Hillenbrand; E Wu; J M Bundy; J P Finn; R M Judd
Journal:  Radiology       Date:  2001-01       Impact factor: 11.105

Review 4.  Myocardial contrast echocardiography in acute myocardial infarction.

Authors:  Flordeliza S Villanueva
Journal:  Am J Cardiol       Date:  2002-11-18       Impact factor: 2.778

5.  Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz-Schatz stents.

Authors:  R Hoffmann; G S Mintz; R Mehran; A D Pichard; K M Kent; L F Satler; J J Popma; H Wu; M B Leon
Journal:  J Am Coll Cardiol       Date:  1998-01       Impact factor: 24.094

6.  Early contrast-enhanced MRI predicts late functional recovery after reperfused myocardial infarction.

Authors:  W J Rogers; C M Kramer; G Geskin; Y L Hu; T M Theobald; D A Vido; S Petruolo; N Reichek
Journal:  Circulation       Date:  1999-02-16       Impact factor: 29.690

7.  Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI. Potential mechanisms.

Authors:  J A Lima; R M Judd; A Bazille; S P Schulman; E Atalar; E A Zerhouni
Journal:  Circulation       Date:  1995-09-01       Impact factor: 29.690

8.  Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion.

Authors:  K C Wu; R J Kim; D A Bluemke; C E Rochitte; E A Zerhouni; L C Becker; J A Lima
Journal:  J Am Coll Cardiol       Date:  1998-11-15       Impact factor: 24.094

9.  Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog.

Authors:  R L Engler; G W Schmid-Schönbein; R S Pavelec
Journal:  Am J Pathol       Date:  1983-04       Impact factor: 4.307

10.  The "no-reflow" phenomenon after temporary coronary occlusion in the dog.

Authors:  R A Kloner; C E Ganote; R B Jennings
Journal:  J Clin Invest       Date:  1974-12       Impact factor: 14.808

View more
  21 in total

Review 1.  Established and emerging cardiovascular magnetic resonance techniques for the assessment of stable coronary heart disease and acute coronary syndromes.

Authors:  David P Ripley; Manish Motwani; Sven Plein; John P Greenwood
Journal:  Quant Imaging Med Surg       Date:  2014-10

2.  Time-dependency, predictors and clinical impact of infarct transmurality assessed by magnetic resonance imaging in patients with ST-elevation myocardial infarction reperfused by primary coronary percutaneous intervention.

Authors:  Suzanne de Waha; Ingo Eitel; Steffen Desch; Georg Fuernau; Philipp Lurz; Deniz Haznedar; Matthias Grothoff; Matthias Gutberlet; Gerhard Schuler; Holger Thiele
Journal:  Clin Res Cardiol       Date:  2011-11-10       Impact factor: 5.460

3.  Relationship and prognostic value of microvascular obstruction and infarct size in ST-elevation myocardial infarction as visualized by magnetic resonance imaging.

Authors:  Suzanne de Waha; Steffen Desch; Ingo Eitel; Georg Fuernau; Philipp Lurz; Anja Leuschner; Matthias Grothoff; Matthias Gutberlet; Gerhard Schuler; Holger Thiele
Journal:  Clin Res Cardiol       Date:  2012-06       Impact factor: 5.460

4.  Relationship between residual viable myocardium and LV remodeling post-MI: Only part of the story.

Authors:  Robert J Gropler
Journal:  J Nucl Cardiol       Date:  2016-02-17       Impact factor: 5.952

Review 5.  Non-invasive imaging of microvascular damage.

Authors:  L Galiuto; L Natale; L Leccisotti; G Locorotondo; A Giordano; L Bonomo; F Crea
Journal:  J Nucl Cardiol       Date:  2009-08-25       Impact factor: 5.952

6.  Acute myocardial infarction: early CT aspects of myocardial microcirculation obstruction after percutaneous coronary intervention.

Authors:  Charles Amanieu; Ingrid Sanchez; Simona Arion; Eric Bonnefoy; Didier Revel; Philippe Douek; Loic Boussel
Journal:  Eur Radiol       Date:  2013-05-08       Impact factor: 5.315

Review 7.  Coronary microvascular dysfunction: mechanisms and functional assessment.

Authors:  Paolo G Camici; Giulia d'Amati; Ornella Rimoldi
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

Review 8.  Cardiac MRI: a central prognostic tool in myocardial fibrosis.

Authors:  Bharath Ambale-Venkatesh; João A C Lima
Journal:  Nat Rev Cardiol       Date:  2014-10-28       Impact factor: 32.419

9.  Gender differences in contrast-enhanced magnetic resonance imaging after acute myocardial infarction.

Authors:  Birgit Langhans; Tareq Ibrahim; Jörg Hausleiter; Carolin Sonne; Stefan Martinoff; Albert Schömig; Martin Hadamitzky
Journal:  Int J Cardiovasc Imaging       Date:  2012-10-09       Impact factor: 2.357

10.  Relation of the ischaemic substrate to left ventricular remodelling by cardiac magnetic resonance at 1.5 T in rabbits.

Authors:  Nicolas Mansencal; Renaud Tissier; Jean-François Deux; Bijan Ghaleh; Nicolas Couvreur; Mario Rienzo; Pascal Guéret; Alain Rahmouni; Alain Berdeaux; Jérôme Garot
Journal:  Eur Radiol       Date:  2009-11-21       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.